
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
Tenaya Therapeutics Inc. has demonstrated promising early clinical data, with protein levels in Patient 1 showing a significant increase of over 50% from Week 8 to Week 52, indicating positive biological activity of its TN-401 gene therapy candidate. The recent receipt of an $8 million CLIN2 grant from the California Institute of Regenerative Medicine (CIRM) further strengthens the company's financial position and enhances its ability to fund ongoing clinical research. Additionally, the company's strategic focus on rapid advancement through clinical development and potential expansion into other indications positions Tenaya for significant upside potential in the future.
Bears say
Tenaya Therapeutics Inc faces significant risks that could adversely affect its financial outlook, particularly related to potential delays in transitioning its preclinical assets to clinical trials and the emergence of safety signals during those trials. The complexities associated with manufacturing AAV-based gene therapy products could further constrain the company’s development and commercialization efforts, impacting forecasts and market sentiment. Additionally, if the company fails to secure adequate funding or experiences setbacks in clinical trials, it may face downward revisions to its financial estimates and valuation.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares